Show simple item record

dc.contributor.authorMarabelle, Aen_US
dc.contributor.authorAndtbacka, Ren_US
dc.contributor.authorHarrington, Ken_US
dc.contributor.authorMelero, Ien_US
dc.contributor.authorLeidner, Ren_US
dc.contributor.authorde Baere, Ten_US
dc.contributor.authorRobert, Cen_US
dc.contributor.authorAscierto, PAen_US
dc.contributor.authorBaurain, J-Fen_US
dc.contributor.authorImperiale, Men_US
dc.contributor.authorRahimian, Sen_US
dc.contributor.authorTersago, Den_US
dc.contributor.authorKlumper, Een_US
dc.contributor.authorHendriks, Men_US
dc.contributor.authorKumar, Ren_US
dc.contributor.authorStern, Men_US
dc.contributor.authorÖhrling, Ken_US
dc.contributor.authorMassacesi, Cen_US
dc.contributor.authorTchakov, Ien_US
dc.contributor.authorTse, Aen_US
dc.contributor.authorDouillard, J-Yen_US
dc.contributor.authorTabernero, Jen_US
dc.contributor.authorHaanen, Jen_US
dc.contributor.authorBrody, Jen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2019-02-04T14:22:03Z
dc.date.issued2018-11-01en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/30295695en_US
dc.identifier5123506en_US
dc.identifier.citationAnn Oncol, 2018, 29 (11), pp. 2163 - 2174en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3043
dc.identifier.eissn1569-8041en_US
dc.identifier.doi10.1093/annonc/mdy423en_US
dc.description.abstractA European Society for Medical Oncology (ESMO)-sponsored expert meeting was held in Paris on 8 March 2018 which comprised 11 experts from academia, 11 experts from the pharmaceutical industry and 2 clinicians who were representatives of ESMO. The focus of the meeting was exclusively on the intratumoral injection/delivery of immunostimulatory agents with the aim of harmonizing the standard terms and methodologies used in the reporting of human intratumoral immunotherapy (HIT-IT) clinical trials to ensure quality assurance and avoid a blurring of the data reported from different studies. The goal was to provide a reference document, endorsed by the panel members that could provide guidance to clinical investigators, pharmaceutical companies, ethics committees, independent review boards, patient advocates and the regulatory authorities and promote an increase in the number and quality of HIT-IT clinical trials in the future. Particular emphasis was placed not only on the development of precise definitions to facilitate a better understanding between investigators but also on the importance of systematic serial biopsies as a driver for translational research and the need for the recording and reporting of data, to facilitate a better understanding of the key processes involved.en_US
dc.format.extent2163 - 2174en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleStarting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1093/annonc/mdy423en_US
rioxxterms.licenseref.startdate2018-11-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfAnn Oncolen_US
pubs.issue11en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublisheden_US
pubs.volume29en_US
pubs.embargo.termsNot knownen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/